AstraZeneca - GBP

AstraZeneca's Tagrisso has received European Commission approval for treating advanced non-small cell lung cancer, showing a median progression-free survival of over three years in late-stage trials.

The FDA revoked the emergency use authorization for AstraZeneca's Evusheld due to its expired shelf life and lack of patient administration approval for over a year.